Slingshot members are tracking this event:

Phase 2 data of TV-45070 for Postherpetic neuralgia due 1H 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
XENE Community voting in process
TEVA Community voting in process

Additional Information

Additional Relevant Details
  • Xenon's partner Teva Pharmaceutical Industries Ltd. is conducting a randomized, double-blind, placebo-controlled Phase 2 clinical trial for TV-45070 in patients with post-herpetic neuralgia, with results initially expected in the second half of 201, but got delayed to 2H 2017.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 27, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2b Data, Tv-45070, Postherpetic Euralgia, 2h 2016